Sophie and her husband will spend over £100,000 traveling between England and New York for IVF treatment that includes embryo screening to select their baby's sex. Their six-year-old son has profound autism, and a UK genetics consultant advised that male siblings face higher recurrence risks. British law prohibits this use of PGT-A technology domestically.

The Human Fertilisation and Embryology Authority (HFEA) banned sex selection for non-medical reasons, but UK-based fertility clinics report increasing numbers of patients traveling abroad. Some seek PGT-A for health reasons, while others pursue experimental PGT-P screening claiming to predict traits like intelligence. The European Society for Human Genetics calls PGT-P "unproven" and "unethical."

Critics argue current science doesn't support PGT-P's predictive claims, and HFEA officials warn it may reduce successful pregnancy chances. However, fertility specialists contend that regulating these technologies in the UK would eliminate reliance on unregulated overseas clinics. The market for reproductive genetic testing continues expanding despite ethical concerns.